- Non-invasive sampling method
- User-friendly collection device, suitable for both men and women
- Eliminate the challenge of urine flow interruption
- Hygienic self-sampling at home, no clinical settings required
- Provide a biopsy when tissue is an issue (biopsy on hard to reach tumor)
- Designed to capture the first-void (first 20 ml of the urine sample)
- Volumetric sample, eliminating aliquot bias
- Scalable solution compatible with routine sample processing
Colli-Pee® | FV-5000

First-void urine collection device for diagnostic applications.
Colli-Pee is a collection device for the collection of first-void urine (the first 20 ml of a urine sample) suitable for use in detection of sexually transmitted infections (STIs)1, early stage cancer screening (prostate2, kidney3, bladder3, pancreas4, lung5 and breast6 cancer) and disease follow-up
Colli-Pee is a non-invasive, user-friendly, self sampling device suitable for use in downstream infectious disease testing, biomarker discovery and diagnostic assays requiring first-void urine sample.
Intended use: Colli-Pee device, FV-5000 series is a first-void urine 20 ml (18-22 ml) specimen collection device suited for both men and women.
User Benefits
Key Features
User Instructions : 6 Easy Steps

Colli-Pee
|
|
---|---|
Gender | Men & Women |
Volumetric sample | 20 ml |
Overall Size | 210 x 105 x 46 mm |
Standardized format for high-throughput processing | ✔ |
1 Human Papilloma Virus (HPV), Chlamydia trachomatis, Neisseria gonorrhoea, Trichomonas and Mycoplasma genitalium.
2T. Govers et al. Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study. Prostate Cancer and Prostatic Diseases (2018)
3Lin SY, et al. Emerging Utility of Urinary Cell-free Nucleic Acid Biomarkers for Prostate, Bladder, and Renal Cancers. Eur Urol Focus (2017)
4R Roy et al. Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies. British Journal of Cancer (2014)
5Aleksandra Franovic, et al. Urine test for EGFR analysis in patients with non-small cell lung cancer. J Thorac Dis (2017)
6Z. Liu et al. Association of urinary and plasma DNA in early breast cancer patients and its links to disease relapse. Clinical and Translational Oncology (2018)
Full terms and conditions for all DNA Genotek products are available here.
DNA Genotek's sample collection devices and nucleic acid stabilization chemistries are protected by issued and pending patents in numerous countries around the world.
“ I am convinced that the non-invasive character of urine sampling, with option of home collection, will definitely help to enroll underserved women in cervical cancer screening and follow-up programs across the world. ”
Alex Vorsters, Ph.D.
Project Group Leader HPV VAXINFECTIO (University of Antwerp)